Internal FDA Menaflex Investigation Finds Serious Process Deviations
This article was originally published in The Gray Sheet
An internal evaluation of FDA's handling of the controversial 510(k) clearance of a knee implant unearthed serious shortcomings in the integrity of the agency's review process, FDA said Sept. 24
You may also be interested in...
HeartWare International names Katrin Leadley chief medical officer. Former CMS Deputy Administrator Jonathan Blum to join CareFirst Blue Cross, while former FDA Deputy Commissioner Sharfstein joins Johns Hopkins. Propeller Health taps senior VP for business and client development.
FDA’s device center is responding to input from HHS’ Office of Inspector General, which was outlined in a June 5 report concluding that gaps remain in processes to ensure all relevant scientific opinions are heard within CDRH.
FDA Principal Deputy Commissioner Joshua Sharfstein relinquished his post Jan. 7 to become secretary of the Maryland Department of Health and Mental Hygiene.